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http://www.biomedcentral.com/1471-230X/14/52RESEARCH ARTICLE Open AccessShort term micronutrient-antioxidant
supplementation has no impact on a serological
marker of gastric atrophy in Zambian adults:
retrospective analysis of a randomised controlled
trial
Violet Kayamba1*, Mumba Chomba1 and Paul Kelly1,2Abstract
Background: Gastric cancer is a major contributor to cancer deaths in Zambia but, as elsewhere, no preventive
strategies have been identified. We set out to investigate the possibility of reducing gastric atrophy, a premalignant
lesion, using micronutrient-antioxidant supplementation.
Methods: We analysed 215 archival samples from a randomised controlled trial of micronutrient-antioxidant
supplementation carried out from 2003 to 2006. Participants were randomised to receive either the supplement or
placebo and had been taking the allocated intervention for a mean of 18 (range 14–27) months when the samples
used in this study were taken. We used low pepsinogen 1 to 2 (PEP1:2) ratio as a surrogate marker of gastric
atrophy. A PEP 1:2 ratio of less than three was considered low. HIV serology, age, nutritional status, smoking, alcohol
intake and gastric pH were also analysed. Ethical approval was obtained from the University of Zambia Biomedical
Research Ethics Committee (011-04-12). The randomized trial was registered (ISRCTN31173864).
Results: The overall prevalence of low PEP 1:2 ratio was 15/215 (7%) and it did not differ between the placebo
(8/103, 7.8%) and micronutrient groups (7/112, 6.3%; HR 1.24; 95% CI 0.47-3.3; P = 0.79). The presence of low PEP 1:2
ratio was not influenced by HIV infection (HR 1.07; 95% CI 0.37-3.2; P =0.89) or nutritional status but it inversely
correlated with gastric pH (Spearman’s rho = −0.34; P = 0.0001). Age above 40 years was associated with atrophy,
but neither alcohol nor smoking had any influence.
Conclusion: Short term micronutrient supplementation does not have any impact on PEP 1:2 ratio, a serological
marker of gastric atrophy. PEP 1:2 ratio inversely correlates with gastric pH.Background
Gastric cancer is a major contributor to cancer deaths in
Zambia but, as elsewhere, no appreciable preventive
strategies have been identified. Low intake of fruits and
vegetables has been associated with increased risk of
gastric adenocarcinoma in the United States of America
[1]. This appears to be also true for patients in Zambia,
as we reported in a case control study that low fruit* Correspondence: viojole@yahoo.com
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reproduction in any medium, provided the orintake in the diet was associated with gastric cancer [2].
Furthermore, isoprostane excretion was increased in
cancer cases, suggesting that the association with low
fruit intake might be mediated via antioxidant status.
While cancer is associated with poor antioxidant status,
it is less well established if the same applies to premalig-
nant lesions.
The sequence of gastric premalignant lesions was first
defined by Correa in 1975 [3]. Premalignant lesions in-
clude atrophy, intestinal metaplasia and dysplasia [4].
These are believed to be present for several years before
undergoing malignant transformation. The best prospectal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Composition of the micronutrient tablet
Micronutrient Amount Reference Nutrient
Intake (RNI)
Beta-Carotene 4.8 mg 4.2 mg equivalent
Ascorbic acid (vitamin C) 70 mg 40 mg
Cholecalciferol (vitamin D3) 5 μg _
Tocopherol (vitamin E) 10 mg 4 mg (uncertain)
Thiamine (vitamin B1) 1.4 mg 1.0 mg
Riboflavin (vitamin B2) 1.4 mg 1.3 mg
Niacin 18 mg 17 mg
Pyridoxine (vitamin B6) 1.9 mg 1.4 mg
Cyanocobalamin (vitamin B12) 2.6 μg 1.5 μg
Folic acid 400 μg 200 μg
Iron 30 mg 14.8 mg (women),
8.7 mg (men)
Zinc 15 mg 9.5 mg
Copper 2 mg 1.2 mg
Selenium 65 μg 75 μg
Iodine 150 μg 140 μg
RNI from reference [21].
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or reverse these lesions, using an intervention which
addresses some fundamental aspect of carcinogenesis.
Repeated endoscopy would be a good way to evaluate
presence or reversal of premalignant lesions, but it is in-
vasive and not without sampling error. Low pepsinogen
1 to 2 ratio (PEP 1:2) has been shown to correlate very
well with gastric atrophy [5-8] and is thus an attractive
alternative for determining the presence of gastric atro-
phy. We have previously shown that the prevalence of
serologically diagnosed gastric atrophy among patients
with normal upper gastrointestinal endoscopies was as
high as 28% (26/94) with 23% (6/26) of these being less
than 45 years old [9].
There is conflicting evidence regarding the benefit of
micronutrient supplementation in premalignant gastric
lesions. Most studies have failed to sufficiently prove any
beneficial effect of this supplementation on the progres-
sion to gastric cancer [10-12]. Vitamin C has no effect
on the reduction of infections in patients with gastric
atrophy [13]. However, other studies have shown that
there is significant regression of gastric atrophy after
anti-oxidant supplementation [1,14]. The findings in the
large trial in Linxian, China, showed that giving beta-
carotene, vitamin E and selenium supplements for 5 years
had an effect on the reduction of gastric cancer risk [15].
A study done in mice showed that vitamin C supple-
mentation does not protect against Helicobacter pylori
(H. pylori) gastritis or gastric premalignancy [16]. Beno
et al. [17] reported that the serum levels of vitamins A,
C and E, selenium, zinc and copper were low in patients
with premalignant gastric lesions in Slovakia.
These studies mainly investigated the effects of vitamins
C, E, A and selenium, and did not include other micronu-
trients. These studies also used histological changes to
assess gastric atrophy. We set out to test the hypothesis
that micronutrient and antioxidant supplementation
could lead to the regression of gastric atrophy determined
by low PEP 1:2 ratios in a Zambian population.
Methods
This was a retrospective analysis of samples from a rando-
mised, placebo-controlled trial of multiple micronutrient
and antioxidant supplementation which was conducted
in Misisi Township in Lusaka, Zambia between 2003
and 2006 [18]. Misisi is one of the poorest and most
densely populated townships in Lusaka, with a preva-
lence of H. pylori infection of 81% [19]. For this study,
we used samples collected in 2005 from volunteers who
had been in the trial for not less than 12 months. As the
allocation was random, it was assumed that at the start
of the study the proportion of subjects with gastric atro-
phy would be the same in both groups, and thus any
difference noted at the end of the study would beattributable to the supplementation. Ethical approval
was obtained from the University of Zambia Biomedical
Research Ethics Committee, ref 011-04-12. The random-
ized trial was registered as ISRCTN31173864.Conduct of the trial during which samples were collected
During the controlled trial, all consenting residents above
the age of 18 years, living in the designated area were eli-
gible to participate in the study. There were no exclusion
criteria. In total, 500 residents volunteered to participate
in the study, half of whom were randomly allocated to re-
ceiving either micronutrient supplementation or placebo.
The multiple micronutrient and the placebo tablets
were both prepared and supplied by Dnask Farmaceutic
Industri (Ballerup, Denmark). The supplement tablets
contained multiple micronutrients at around 1.5-2 times
Recommended Nutrient Intakes (Table 1). Details of the
randomization have been previously reported [18]. Blood
samples were collected from these volunteers at the start
of the study and annually until the end of the study, and
stored at −80°C in a secure laboratory. Compliance was
measured by counting unused pills and was estimated at
95% [18]. Nutritional assessment at baseline included
height, weight (to determine the body mass index), and
mid upper arm circumference; fat mass and lean mass
were measured by impedance (Body Stat 1500, Douglas,
Isle of Man, UK). Gastric pH, measured in fasting par-
ticipants by endoscopic aspiration of gastric juice, was
measured as previously described [20].
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To determine the presence of severe gastric atrophy,
PEP 1:2 ratios were determined using ELISA kits for
pepsinogen 1 and 2 (Biohit, Helsinski, Finland) and the
manufacturer’s instructions were followed. A ratio less
than 3.0 was used to signify the presence of severe gas-
tric atrophy. VK and MC were completely blinded to
the allocations while running the samples. The coding
of these samples was only broken by PK after comple-
tion of data entry.Data analysis
Statistical analysis was carried out using STATA 12.1
(STATA Corp. College Station. TX). For continuous var-
iables showing Gaussian distribution, the Kruskal-Wallis
test was used to compare the two groups. For categorical
variables, Fisher’s exact test was used. Backwards step
wise unconditional logistic regression was used to assess
the contributions of different factors to gastric atrophy.Figure 1 Flow charts showing how the final samples analysed were oResults
A total of 226 serum samples collected in 2005 were
available for analysis. Eleven samples were, however, left
out of the analysis as three were not clearly labelled and
eight were collected after crossover from micronutrient
to placebo in the original trial [18], leaving a total of 215
samples. The flow of collected samples used in this study
was as outlined in Figure 1. Subjects from whom these
samples were collected had therefore received either
micronutrient supplementation for a median of 18 months
(IQR 16–19) or placebo for 19 months (IQR 18–20).
Demographic characteristics and potential confounders
are shown in Table 2.
Gastric atrophy (low PEP 1:2 ratio)
The overall prevalence of gastric atrophy in these healthy
volunteers was 15/215 (7%). There was no significant dif-
ference in the prevalence of low PEP 1:2 ratios between
the participants on micronutrient supplementation, 8/103
(7.8%) and those on placebo, 7/112 (6.3%) Hazard Ratiobtained.
Table 2 Demographic characteristics of the participants
Supplementation group (n = 103) Placebo group (n =112) P
Mean age in years 37+/−13 37.1+/−13 0.869
Number of females n (%) 70 (68.0) 71 (63.4) 0.566
Education n (%)
Primary 73 (70.9) 88 (78.5)
Secondary or better 30 (29.1) 24 (21.4) 0.333
Mean Body Mass Index (kg/m2) 22.6+/−3.8 22.8+/−5.9 0.581
HIV positive n = 66 (%) 32 (48.4) 34 (51.5) 0.592
Mean Middle Upper Arm Circumference (MUAC) 27.3+/−3.3 27.4+/−4.2 0.705
Mean Body fat (kg) 29.9+/−9.4 29.5+/−9.8 0.547
Mean Lean mass (kg) 70.0+/−9.3 69.9+/−11.0 0.630
Median (IQR) follow up (months) 18 (16–19) 19 (18–20) 0.0001
pH n = 121 3.3+/−2.2 3.2+/−2.2 0.881
Tobacco use n (%) 15 (14.5) 23 (20.5) 0.286
Cannabis n (%) 4 (3.8) 2 (1.8) 0.430
Alcohol n (%) 18 (16.1)
Everyday 12 (11.6) 18 (16.1)
Not every day 39 (37.9) 33 (29.5) 0.661
Table 3 Correlation with pepsinogen 1:2 ratio
Spearman’s ρ P value
pH (n = 121) −0.345 0.0001
BMI −0.003 0.967
MUAC 0.005 0.947
Body fat −0.107 0.122
Lean mass 0.075 0.280
Impedance −0.043 0.542
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1:2 ratios of all the samples as continuous variables did
not yield any statistically significant difference (P = 0.32).
The mean ratio among the supplementation group was
5.8 (IQR 4.3-6.9), while that among the placebo group was
5.9 (IQR 4.5-8.0).
HIV infection
Of the serum samples analysed, 180 had HIV tests per-
formed in the previous trial, and 66 (37%) were positive.
Of these subjects with HIV infection, 5/66 (7.6%) had
gastric atrophy, which did not differ significantly from
HIV negative subjects among whom 8/114 (7.0%) had
atrophy (HR 1.07; 95% CI 0.37-3.2; P =0.89).
Gastric pH
Measurements of pH in gastric aspirates taken while
fasting were available on 121 participants. Gastric pH and
low PEP 1:2 ratios were inversely correlated (Spearman’s
rho = −0.34; P = 0.0001). Of the 60 participants rando-
mised to placebo for whom pH measurements were
available, 19 (32%) had a fasting gastric pH of more
than 4 (which was taken as significant hypochlorhydria)
compared to 26 of 61 (43%) participants allocated to
micronutrient-antioxidant supplementation (HR 1.35,
CI 0.84-2.16, P = 0.26).
Nutritional status
Parameters of nutritional status analysed in the main trial
were considered in this analysis. There was no correlation
between gastric atrophy and nutritional status (Table 3).Multivariate analysis
A multivariate logistic regression was carried out includ-
ing several factors to try and ascertain any relation to se-
vere gastric atrophy (Table 4). Alcohol and smoking did
not show any influence on gastric atrophy. The amount
of alcohol being consumed was also taken into consider-
ation, and categorised as those taking every day and not
every day. Even after taking this into consideration, there
was still no significant difference between the atrophy
subjects and the ones without atrophy. The only influ-
ence found to be significant was age, as subjects above
the age of 40 years were found to be more at risk of having
gastric atrophy.
Discussion
Gastric cancer remains a major cause of cancer mortality
in Zambia [22]. We set out to investigate the possibility
that micronutrient supplementation could reduce the
occurrence of low PEP 1:2 ratio, which is a surrogate
marker of gastric atrophy. We found that an average of
18 months of micronutrient supplementation made no
Table 4 Logistic regression analysis of atrophy (measured
as low pepsinogen 1:2 ratio) in relation to potential
determinants
Odds ratio 95% CI P
Sex (female) 0.59 0.21-1.66 0.32




HIV positive 1.51 0.44-5.20 0.52
Low education 1.62 0.41-6.43 0.49
Alcohol use 0.85 0.58-1.24 0.40
Tobacco use 0.86 0.17-4.30 0.86
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HIV infection was also found not to have any influence
on atrophy. Gastric atrophy was more likely among par-
ticipants above the age of 40 years, while there was an
inverse correlation with fasting pH, which is consistent
with our previous findings [20]. Alcohol and smoking
also did not show any influence on gastric atrophy.
The study participants were randomly allocated to either
supplementation or placebo in the main trial. We made a
reasonable assumption at since the participants were
randomly allocated at enrolment then the prevalence of
atrophy was not significantly different in the two
groups. It is well understood that any differences in
groups that have been randomly allocated are merely
due to chance [23]. This is a premise on which rando-
mised controlled trials are based. There was essentially
no difference in the basic demographics of the two
groups of participants used in this analysis. However, on
average participants allocated to the placebo group were
followed up for one month longer than the supplementa-
tion group. This was statistically significant (P = 0.0001). If
the supplementation had any effect on development of at-
rophy, this difference would still have been seen despite
the longer follow-up in the placebo group. It seems un-
likely that this difference in duration of follow-up (which
is determined by the date the sample was collected) could
explain a lack of apparent benefit. On the other hand,
18 months might be too short to demonstrate the effect of
these supplementations and it is possible that a longer
follow-up (5–10 years) might yield different results.
Gastroscopies were done on some of the participants in
the main trial to determine the fasting gastric pH. Unfor-
tunately, no gastric biopsies were obtained as this was not
part of that study protocol. We therefore, did not have any
data on the histological diagnosis of gastric atrophy or the
degree of atrophic changes. Analysis of PEP 1:2 ratios as
continuous variables did not yield any statistically signifi-
cant difference between the two groups.
We know from our previous work that the presence of
H. pylori antibodies is very common in this population[19]. H. pylori infection has an influence on the presence
and persistence of gastric atrophy but it was not tested
in the main trial and we did not have the appropriate
samples to test for active infection. Therefore, the pres-
ence of H. pylori infection was not checked in this retro-
spective analysis of stored serum samples. This could
not have affected the results as none of the patients
received treatment to eradicate the infection during the
study follow-up.
The adherence (pill count) of the subjects was at more
than 95%, as reported in the main trial [18]. Participants
were drawn from an impoverished community in Zambia
where micronutrient deficiency is common. If supplemen-
tation had an effect, then it would be more obvious in
such a population than in a generally well nourished com-
munity. Our study was not designed to assess the nutri-
tional impact on intestinal metaplasia, which is another
step in the carcinogenetic pathway.
The population prevalence of gastric atrophy in Zambia
is unknown, but in a hospital based case–control study
[9], we found that up to 28% of healthy controls had sero-
logical evidence of severe gastric atrophy. In this study, we
used serum samples from healthy community volunteers
and found that the prevalence of atrophy was much less at
7%. However, in the current study the mean age was
37 years whereas it was 55 years in the case–control study.
We have demonstrated that gastric atrophy tends to be
more common with advancing age, which could explain
the different prevalence. On the other hand, these findings
might reflect a higher frequency of incipient gastroduode-
nal pathology in hospital based controls.
HIV positive patients have in the past been reported
to have higher gastric pH than their HIV negative coun-
terparts [20]. Neither the aetiology nor the consequence
of this finding is clear. In addition, HIV infection was
not found to be associated with gastric cancer [9]. In this
study, we found no correlation between HIV infection
and gastric atrophy, suggesting that the hypochlorhydria
seen in HIV infection cannot be explained by the loss of
normal gastric mucosa cells. More work still needs to be
done in order to find out why HIV infected patients
have high pH and the consequence of this as there seem
to be no connection with gastric cancer or it precursor
lesions [9].
We were also interested to see if alcohol and smoking
had any influence on gastric atrophy. It remains unclear
at which exact stage (if at all) of the carcinogenic pathway
alcohol and smoking influence gastric carcinogenesis. We
found that these two factors have no influence on gastric
atrophy.
There is a shortage of data on gastrointestinal malignan-
cies in Africa, and further work is needed to determine if
there might be any scope for nutritional interventions to
reduce risk.
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An average of 18 months of micronutrient-antioxidant
supplementation has no impact on the occurrence of
low PEP 1:2 ratio, which is a surrogate marker of gastric
atrophy. The presence of HIV infection has no influence
on atrophy. Low PEP 1:2 ratios were more likely among
participants above the age of 40 years, while there was an
inverse correlation with fasting pH. Alcohol and smoking
also did not show any influence on gastric atrophy.
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